Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$HTGM .71
Rhe 2.44 ** 1.8 mill o/s
IMTE 2.90 one to watch. Huge candle to 12 recently. https://schrts.co/wZDimeNV
CREX news: LOUISVILLE, Ky. and ARLINGTON, Texas , June 28, 2022 (GLOBE NEWSWIRE) -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX, CREXW), a leading provider of digital signage solutions, and Strike Ten Entertainment (“STE”), the marketing arm of the bowling industry, announced a marketing partnership designed to help bowling centers grow their revenues via the role digital signage will play in transforming the food and beverage experience across bowling centers nationwide for proprietors and consumers. The marketing partnership provides a robust, continuous platform for Creative Realities to showcase how its offering can help revolutionize the business of traditional bowling centers for proprietors and enhance the customer experience with modern digital displays.
AGRX 1.70 pre market mover 2.12 hod
$NEPT 1.52 Financial Results on June 29, 2022(WASH SALE)
All Content and Data provided by Third-Parties — Terms of Use
Neptune to Report Fourth Quarter and Fiscal 2022 Financial Results on June 29, 2022
PR NEWSWIRE 5:40 PM ET 6/27/2022
Symbol Last Price Change
NEPT 1.52up 0 (0%)
QUOTES AS OF 04:00:01 PM ET 06/27/2022
Management will host a conference call at 5:00 p.m. ET on the same day
LAVAL, QC , June 27, 2022 /PRNewswire/ - Neptune Wellness Solutions Inc.(NEPT) ("Neptune" or the "Company") , a diversified and fully integrated health and wellness company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will report its financial results for the fourth quarter and full year 2022 after the market closes on Wednesday, June 29, 2022.
Following the release of its financial results, the Company will host a conference call at 5:00 p.m. (Eastern Time) on Wednesday, June 29, 2022, to discuss these results. The conference call will be webcast live and can be accessed by registering on the Events and Presentations portion of Neptune's Investor Relations website at www.investors.neptunewellness.com. The webcast will be archived for approximately 90 days.
About Neptune Wellness Solutions Inc.(NEPT)
Headquartered in Laval, Quebec, Neptune is a diversified health and wellness company with a mission to redefine health and wellness. Neptune is focused on building a portfolio of high quality, affordable consumer products in response to long-term secular trends and market demand for natural, plant-based, sustainable and purpose-driven lifestyle brands. The Company utilizes a highly flexible, cost-efficient manufacturing and supply chain infrastructure that can be scaled to quickly adapt to consumer demand and bring new products to market through its mass retail partners and e-commerce channels. For additional information, please visit: https://neptunewellness.com/.
Disclaimer – Safe Harbor Forward–Looking Statements
Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Neptune Wellness Solutions(NEPT) to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.
Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.
Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neptune-to-report-fourth-quarter-and-fiscal-2022-financial-results-on-june-29-2022-301576217.html
SOURCE Neptune Wellness Solutions Inc.(NEPT)
Good news for the market: Waking the Dragon
China is loosening its COVID-19 restrictions after a wave of recent lockdowns, and investors are taking it as a positive for the US and global economy. China's return to full commercial activity could provide relief for strained supply chains and global inflation.
GM RDHL continuation $1.05 and 1.11 new highs. Chart https://schrts.co/ymceqNxG
$AEI Impact BioMedical Announces License Agreement with ProPhase Labs (NASDAQ: PRPH $12.98) to Produce and Distribute Viral-Fighting Compound Equivir
https://finance.yahoo.com/news/impact-biomedical-announces-license-agreement-120000349.html
Impact Biomedical, Inc., a wholly owned subsidiary of DSS
$AEI Owns 28.2% of DSS, from last Q
Zacks Small-Cap Research on DSS Valuation $1
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_05192022_DSS_Thompson.pdf
$TOUR .90
I wouldn't be surprised if they do
$TOUR $0.79
$PBLA .86 news, still has not recovered since Russell rebalance (1.10 area):
MINNEAPOLIS , June 28, 2022 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc.- (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the publication of preclinical data from studies of SBP-101 that demonstrated a 42% increase in median survival in a mouse model of VDID8+ ovarian cancer. Data published in the International Journal of Molecular Sciences also showed SBP-101 delayed tumor progression and decreased the overall tumor burden. SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. The company expects to initiate an ovarian cancer clinical program for SBP-101 during 2022.
“This data highlights the importance of polyamines as a cancer therapeutic. These preclinical studies are foundational to the expansion of our clinical development program. We look to expand SBP-101 into ovarian cancer, and later the potential for other cancers. This compliments our current clinical development program with SBP-101’s ongoing global randomized trial (ASPIRE) in first-line metastatic pancreatic cancer, and eflornithine in combination with an anti PD-1 into non-small cell lung cancer (NSCLC) to begin later this year,” said Jennifer K. Simpson , PhD, MSN , CRNP, President & Chief Executive Officer of Panbela. “We look forward to advancing our development program for SBP-101 and eflornithine into the clinic for ovarian cancer and NSCLC indications to help as many patients as possible.”
Rhe $2.35 **** 1.7 mill o/s*****
AGRX 12x the O/S traded yesterday......up 37% now....they can blow it up today...
CYTO @ .60s: FDA clearance on 6/27 unnoticed for tiny CYTO w/16.6M float. Has all elements of ripper
Serious good news that was simply overlooked.
Link.
https://finance.yahoo.com/news/altamira-therapeutics-receives-fda-510-123000252.html
Still under 50m market cap. LOL. How far they gonna run it? 200m?
EVFM money train
FEMY I wasn't;t suggesting that it couldn't /wouldn't go up, just that it is NOT the same as EVFM as some have suggested. Good luck trading.
EVFM > 1.53 > Huge news out 20 minutes ago: Evofem Reaches Agreement with One of the Largest Pharmacy Benefit Managers in the U.S. for Access to Phexxi(R)
6:48 am ET June 28, 2022 (PR Newswire)
FEMY 2.80
EVFM - $1.34 - Moving higher in PM on news...
https://www.prnewswire.com/news-releases/evofem-reaches-agreement-with-one-of-the-largest-pharmacy-benefit-managers-in-the-us-for-access-to-phexxi-301576452.html
MREO @ $150s: Buyout/BidWar. $5 offer from AstraZ. Novartis is hunt too. Major ripper all week. Get in in pre-market. MREO getting found. News at any time.
Augusta great game last night. Must have been tricky who to be for. All those people that left in the 8th inning with 2-0 Atlanta must have been shocked when they got home. Dodgers pulled a hat trick at the end.
$BJDX 8x34 cross tomorrow
Maybe Aspira Women’s Health (AWH)
Maybe not
XELA showing 460M float! Is there a bottom here?
RHE $2.35 **** 1.8 Mill o/s *****
XELA-- being pushed down with synthetic shares...
We all here made multiple profitable trades with FEMY. We all made multiple profitable trades with EVFM. > Relax! ..... Good luck with your research.
FEMY ??? They don't have anything on the market as of yet, all they have is preclinical research for fertility drugs,,, NOT BIRTH CONTROL> EVFM Phexxi IS FDA approved and on the market and sales are growing exponentially. Do your research peeps.
XELA-- Shouldnt be this low with last weeks news! JMO
Exela Technologies Secures XBP Contract Totaling $136M
8:30 am ET June 22, 2022 (Benzinga) Print
Exela Technologies Secures XBP Contract Totaling $136 Million
$175 million in XBP TCV signed in 2022 YTD
IRVING, Texas, June 22, 2022 (GLOBE NEWSWIRE) -- Exela Technologies, Inc. ("Exela") (NASDAQ:XELA, XELAP)))) today announced a new customer win of $136 million in total contract value ("TCV") over three years bringing the year-to-date XBP TCV wins to $175 million.
Exela's Exchange for Bills and Payments ("XBP"), the largest revenue contributor of the $874.2 million ITPS accounting segment for FY 2021, continues to sign new logos including 5 new XBP logos in 2022. This integrated solution utilizes several of Exela's platforms including TMS® for payment processing, its collaborative Beats® workflow and digital mailroom ("DMR") delivering a bespoke digital solution used by Exela's knowledge workers and its customers.
"This win highlights our scalable, referenceable XBP platforms effectiveness for rapid deployment for our customers. We are excited by the positive reception for our market-ready solutions that leverages our extensive experience in the payment space", noted Lakshmi Narayanan Chandramohan, President - Bills and Payments
Exela is a leader in Bills and Payment processing with our XBP liquidity solutions enabling billers, consumers and businesses to communicate and transact. XBP offers a complete solution to its customers and enables improved control, insights, and analytics globally.
EVFM - when the gang gets to shorting, there shall be much wailing and gnashing of teeth.
PRFX 1.03 most volume came within 30 minutes today. If that kept up all day, this could move fast.
Followers
|
2516
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
642225
|
Created
|
06/03/08
|
Type
|
Free
|
Moderator AugustaFriends | |||
Assistants jobynimble JDUB Mark |
Sign up for Email Updates: http://investorshub.advfn.com/boards/chairmail_sub.asp?board_id=12753
Chart Lessons by IAMGEND - A must learn for all traders
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=76625096
Chart tools:
(1) I use http://www.stockcharts.com for charting
(2) For more info on chart formations, see http://www.chartpatterns.com
(3) Chart indicator definitions http://stockcharts.com/education/IndicatorAnalysis/
(4) Explore Level II here-http://www.hotstockmarket.com/forums/showthread.php?t=14938
(5) For a COMPLETE list of indicator meanings http://www.investopedia.com/categories/technicalanalysis.asp
(6) Top insider trades website: http://www.secform4.com/top-lists.htm
BOARD FOR IHUBS HOTTEST CHART PLAYS
http://investorshub.advfn.com/boards/board.aspx?board_id=18372
WHO'S HOT: http://investorshub.advfn.com/boards/hot_people.asp
CHART YOUR STOCKS HERE: http://stockcharts.com/index.html http://www.profitspi.com/
INSTANT TECHNICAL ANALYSIS: http://www.barchart.com/
NEWS FILTER: http://www.marketwatch.com/
GOOD READ: http://www.bloggingstocks.com/
ALL ABOUT TRADERS: http://www.tradersmagazine.com/
TRACK WHAT THE FUNDS ARE DOING - MY FAVORITE SITE!: http://www.mffais.com
COMMENTARY ON EVERYTHING STOCKS: http://www.istockanalyst.com/
BEST ONLINE BROKERAGE:http://www.nobletrading.com/index.php (ask for Efrain)
MARKET MAKERS: http://www.otcbb.com/dynamic/tradingdata/download/mmids.txt
SHORT DATA: http://shortsqueeze.com/
SEC FILINGS: http://www.sec.gov/edgar/searchedgar/companysearch.html
WALL STREET TABLOID: http://dealbreaker.com/
Posts Today
|
3
|
Posts (Total)
|
642225
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |